Isabel Gordaliza-Alaguero

1 minute reading time

Dr. Isabel Gordaliza-Alaguero is a biomedical scientist and Regulatory Affairs professional with a strong motivation to translate laboratory innovations into practical solutions that improve patients’ lives. Since March 2025, she has been Head of Regulatory Affairs at LentiCure.

Isabel Gordaliza-Alaguero

  • Regulatory Affairs Manager at LentiCure since March 2025. 

  • Regulatory Affairs Officer for lentiviral gene therapies at Erasmus MC between 2022 and 2025. During her time at Erasmus MC, the lentiviral gene therapy for Pompe disease received the Orphan Designation from the European Medicines Agency (EMA).  

  • PhD researcher at the Institute for Research in Biomedicine (Barcelona, ​​Spain) between 2016 and 2021. During her PhD, she studied intracellular processes related to cellular recycling mechanisms known as autophagy, resulting in multiple scientific publications.

  • More information on LinkedIn

About Isabel Gordaliza-Alaguero

Isabel is a highly analytical and versatile professional with a passion for continuous learning and exploring new disciplines. Driven by the desire to create meaningful change, she focuses on transformative projects that have a lasting positive impact on society. She believes that teamwork and collaboration between all stakeholders are essential to solving complex societal challenges.

Laatste nieuws

Letstalkbusiness (1)

Podcast: Research is the key – Let’s Talk Business

Tuesday, January 20, 2026

The Prinses Beatrix Spierfonds funds, guides, and stimulates scientific research into muscle diseases, because it knows that scientific research is the only key to making all muscle diseases treatable in the future. Listen to the New Business Radio podcast Let’s Talk Business #634.

Lees meer
Kathinka Header Gespiegeld

Donate to the Spierfonds and make a difference

Tuesday, January 20, 2026

Every day, people with a muscle disease need our help. With your donation, you help make groundbreaking research possible, improve treatments, and give hope to thousands of people in the Netherlands. Discover why your contribution can have such an impact.

Lees meer

We have never been more hopeful

Tuesday, January 20, 2026

Start-up for gene therapy for Pompe disease. With the collaboration between Erasmus MC and the start-up LentiCure, the Prinses Beatrix Spierfonds is taking a new step. The goal is to develop a gene therapy for Pompe disease.

Lees meer